CCR5-Specific Human Monoclonal Antibodies for HIV
Background:
Antibodies are available for
collaborative research toward commercialization and/or exclusive
and non-exclusive licensing. In vitro data is available at this
time.
Technology:
The HIV co-receptor CCR5 has been
demonstrated to play an important role in virus entry. This
invention describes anti-CCR5 monoclonal antibodies, their fusion
protein, conjugates, derivatives, or fragments, DNA sequences
encoding such antibodies, host cells containing such DNA sequences,
as well as the methods to produce them recombinantly and their
pharmacological composition. The subject antibodies exhibited
neutralization activity against HIV-1 infection by binding to cell
associated CCR5 in vitro. Moreover, these antibodies have
potentially lower immunogenicity and toxicity because they are
fully human antibodies. These anti-CCR5 antibodies have potential
as therapeutics and/or prophylactics in combination with other
HIV-1 neutralizing antibodies and anti-retroviral
drugs.
Related Publications:
- C Pastori et al. Long-lasting CCR5 internalization by
antibodies in a subset of long-term nonprogressors: a possible
protective effect against disease progression. Blood. 2006 Jun
15;107(12):4825-4833.
- DS Dimitrov. Fusin - a place for HIV-1 and T4 cells to meet.
Nature Med. 1996 Jun;2(6):640-641.
Contact
Information:
John D. Hewes, Ph.D., NCI
Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #430 JH
Updated 10/25/2007